Full-length recombinant endostatin, with or without an amino-terminal nonamer, has been studied in the clinical setting for anti-angiogenic properties against various cancers, including gastric, nasopharyngeal, glioblastoma multiforme, lung–brain metastases, and two different lung cancers [47,48,49,50,51,52]. The gene discussed is COL18A1; the disease is cancer.